Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...

In the wake of the 2024 U.S. elections, stakeholders in the life sciences and health care industry are intensely focused on the policy ...

A tide change is rippling across healthcare. As industry leaders converged on San Francisco for the 2025 JP Morgan Healthcare conference, they echoed optimism about a renewed stability in healthcare, ...

Another year at the J.P. Morgan Healthcare Conference is in the books. | While major payers skipped out on this year’s event, ...

UNC Health and Duke Health formed a joint venture to build a 500-bed, free-standing children's hospital in the Piedmont, ...

The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...

Radiotherapy, China's biotech surge and AI's role in drug discovery are notable topics that emerged from conversations on the ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of ...

A major conference that took place earlier this month is set to return to San Francisco next year, according to SF Mayor Daniel Lurie’s office. The J.P. Morgan ...

The year ahead in clinical trials looks set to be one that is challenged and influenced by regulatory developments, new ...